clinical trial · NCT06190093
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics, Inc.·phase3·completed·n = 400
Neovascular Age-related Macular DegenerationAge-Related Macular DegenerationWet Macular Degenerationbevacizumabranibizumab
brief summary
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
started
Jan 24, 2024
primary completion
Nov 7, 2024
completion
Dec 5, 2024
last updated
Jun 30, 2026
official title
Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol